Please login to the form below

Not currently logged in
Email:
Password:

Glenmark settles with Astellas/ Triax

Glenmark has settled a US patent infringement suit with Triax Pharmaceuticals and Astellas over a generic version of a cream for inflammation of the skin

India-based generics manufacturer Glenmark has settled a US patent infringement suit with Triax Pharmaceuticals and Astellas over a generic version of a cream for inflammation of the skin.

The suit relates to an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) for a form of hydrocortisone butyrate cream, Glenmark's generic equivalent of Locoid Lipocream, currently registered by Astellas and licensed to Triax.

Under the settlement and licence agreement, Glenmark will be permitted to market and distribute its version of the cream under a royalty-bearing licence from Astellas and Triax in the US by the end of 2013.

In a statement, Glenmark said it believed it was entitled to 180 days of exclusivity to market the product as the first generic company to file a related ANDA.

According to IMS Health data, Locoid Lipocream had sales of around $38m for 2010.

25th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics